News

Video

Osimertinib (osi) After Definitive Chemoradiotherapy (CRT) in Patients (pts) With Unresectable Stage (stg) III Epidermal Growth Factor Receptor-Mutated (EGFRm) NSCLC: Primary Results of the Phase 3 LAURA Study

Author(s):

Suresh S. Ramalingam, MD, FACP, FASCO

The LAURA study (NCT03521154) evaluates the efficacy and safety of Osimertinib as a maintenance therapy following chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer.

Related Videos
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study
Intracranial Efficacy of Datopotamab Deruxtecan in Patients with Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations: Results from Tropion-Lung05
4 KOLs are featured in this series
4 KOLs are featured in this series
John Heymach, MD, PhD
Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: primary results from DESTINY-Breast06
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study
Related Content
Ken Takeshita, MD
June 27th 2024

FDA Issues CRL for Patritumab Deruxtecan in Pretreated EGFR+ NSCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Dave Fredrickson
June 25th 2024

First-Line Osimertinib Plus Chemo Approved in Japan for EGFR+ Advanced NSCLC

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Jorge J. Nieva, MD, of Keck Medicine of University of Southern California
June 25th 2024

Addressing the Logistics of At-Home Cancer Care With Subcutaneous Administration of Immunotherapy

Lyudmila A. Bazhenova, MD, of UC San Diego Health Moores Cancer Center
June 24th 2024

ADCs and TKIs Look to Carve Out Their Place in the HER2-Mutant NSCLC Treatment Paradigm